Showing results (161-170 of 178) with videos related to
Sort By:
Pageof 18
Nature Biomedical Engineering|April 25, 2019
Nanoparticle-mediated local depletion of tumour-associated platelets disrupts vascular barriers and augments drug accumulation in tumoursSuping Li, Yinlong Zhang, Jing Wang, et al.Nature Communications|April 7, 2021
Bioengineered bacteria-derived outer membrane vesicles as a versatile antigen display platform for tumor vaccination via Plug-and-Display technologyKeman Cheng, Ruifang Zhao, Yao Li, et al.Transfusion|October 12, 2011
A comparison of self-reported and record-linked blood donation history in an Australian cohortNadine A Bertalli, Katrina J Allen, Christine E McLaren, et al.Journal of Gastroenterology and Hepatology|October 15, 2014
Natural history of HFE simple heterozygosity for C282Y and H63D: a prospective 12-year studySophie G Zaloumis, Katrina J Allen, Nadine A Bertalli, et al.Nature Biotechnology|February 13, 2018
A DNA nanorobot functions as a cancer therapeutic in response to a molecular trigger in vivoSuping Li, Qiao Jiang, Shaoli Liu, et al.Gastroenterology|October 14, 2008
The natural history of serum iron indices for HFE C282Y homozygosity associated with hereditary hemochromatosisLyle C Gurrin, Nicholas J Osborne, Clare C Constantine, et al.Hepatology (Baltimore, Md.)|January 26, 2010
HFE C282Y homozygotes are at increased risk of breast and colorectal cancerNicholas J Osborne, Lyle C Gurrin, Katrina J Allen, et al.Annals of Hepatology|August 27, 2018
Cirrhosis in Hemochromatosis: Independent Risk Factors in 368 HFE p.C282Y HomozygotesJames C Barton, Christine E McLaren, Wen-Pin Chen, et al.Blood Cells, Molecules & Diseases|December 10, 2016
GNPAT p.D519G is independently associated with markedly increased iron stores in HFE p.C282Y homozygotesJames C Barton, Wen-Pin Chen, Mary J Emond, et al.The Lancet. Haematology|December 3, 2017
Reduction of body iron in HFE-related haemochromatosis and moderate iron overload (Mi-Iron): a multicentre, participant-blinded, randomised controlled trialSim Y Ong, Lyle C Gurrin, Lara Dolling, et al.Pageof 18